Pharmacy Times

JUNE 20, 2025

Blood cancer patients are usually at higher risk due to prior chemotherapy, and maybe we don’t need the same kind of prophylactic medications for solid tumor patients. I think we’re getting to the point now where hematology and oncology both need services that can manage these types of side effects. The infection risks are a little different.

Compounding Pharmacies 65

Compounding Pharmacies Immunization Mayo Clinic Hospitals 65

Pharmacy Times

JUNE 23, 2025

News All News FDA Updates Press Releases Media All Videos Digital Detail Independent Corner Insights Interviews MEDcast Medical World News Microsites Peer Exchange Perfect Consult Podcasts Practice Pearls Sponsored Webcast Student Voices Webinars/Webcasts Conferences Conference Coverage Conference Listing Publications Pharmacy Times Pharmacy Practice (..)

FDA 65

FDA Compounding Pharmacies Dosage Hospitals 65

Pharmacy Times

JUNE 12, 2025

Clinical Applications and Economic Impacts Biologics have significantly impacted cancer therapies by targeting cancer cells more specifically and reducing adverse events compared with traditional chemotherapy, Darkow noted.

Immunization 73

Immunization Compounding Pharmacies FDA Hospitals 73

Pharmacy Times

JUNE 13, 2025

Vitamin D supplementation increased 25-hydroxyvitamin-D levels significantly, suggesting a potential role in enhancing chemotherapy effectiveness. The study's findings support further research with larger samples to explore vitamin D's impact on chemotherapy and breast cancer remission likelihood.

Chemotherapy 141

Chemotherapy Compounding Pharmacies Immunization Hospitals 141

Pharmacy Times

JULY 22, 2025

A man aged 55 years with metastatic colorectal cancer was initiated on a standard fluoropyrimidine-based chemotherapy regimen. Within a week, he developed severe neutropenia, gastrointestinal shutdown, and septic complications requiring admission to the intensive care unit.

Compounding Pharmacies 50

Compounding Pharmacies FDA Hospitals Immunization 50

Pharmacy Times

JUNE 16, 2025

Transportation barriers, as a health-related social need, significantly impact FN rates in chemotherapy patients. Febrile neutropenia (FN) remains a serious and common complication of chemotherapy. A 67% FN rate difference between pegfilgrastim and filgrastim was observed in patients with transportation barriers.

HIV Treatment and Prevention Agents 73

HIV Treatment and Prevention Agents Chemotherapy Compounding Pharmacies Immunization 73

Pharmacy Times

JULY 9, 2025

Although improved clinical outcomes with the addition of chemotherapy to ICI have been recorded for some patients, there is ongoing research to understand how prognostic factors (eg, smoking history, tumor histology, performance status) can provide some predictive values for patient response to ICI therapy.

Immunization 86

Immunization Compounding Pharmacies FDA Chemotherapy 86

Pharmacy Times

JULY 23, 2025

So I think the study really showed the benefit of remote clinical monitoring after starting chemotherapy. Pharmacy Times : What opportunities do pharmacists have to support safe substitution and dosing decisions during drug shortages? Subscribe Now!

Specialty Pharmacies 65

Specialty Pharmacies Hospitals Compounding Pharmacies Immunization 65

Pharmacy Times

JUNE 20, 2025

News All News FDA Updates Press Releases Media All Videos Digital Detail Independent Corner Insights Interviews MEDcast Medical World News Microsites Peer Exchange Perfect Consult Podcasts Practice Pearls Sponsored Webcast Student Voices Webinars/Webcasts Conferences Conference Coverage Conference Listing Publications Pharmacy Times Pharmacy Practice (..)

Compounding 115

Compounding Compounding Pharmacies Patient Care Immunization 115

Pharmacy Times

JUNE 10, 2025

News All News FDA Updates Press Releases Media All Videos Digital Detail Independent Corner Insights Interviews MEDcast Medical World News Microsites Peer Exchange Perfect Consult Podcasts Practice Pearls Sponsored Webcast Student Voices Webinars/Webcasts Conferences Conference Coverage Conference Listing Publications Pharmacy Times Pharmacy Practice (..)

FDA 73

FDA HIV Treatment and Prevention Agents Compounding Pharmacies Hospitals 73

Pharmacy Times

JUNE 9, 2025

link] Newsletter Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights. Subscribe Now!

Compounding Pharmacies 73

Compounding Pharmacies Hospitals Immunization Chemotherapy 73

Pharmacy Times

JUNE 17, 2025

Conclusions We demonstrated the feasibility of leveraging a complex EHR data source from an integrated health system to study the impact of dose modifications on clinical outcomes for self-administered chemotherapy. Nearly half of the patients with CML on imatinib experienced dosage modifications in this study.

Dosage 65

Dosage Compounding Pharmacies Immunization Chemotherapy 65

Pharmacy Times

JUNE 19, 2025

Trends Pharmacol Sci. 2024;45(5):406-418. doi:10.1016/j.tips.2024.03.004

Compounding 65

Compounding Compounding Pharmacies FDA Immunization 65

Pharmacy Times

JUNE 25, 2025

Yes, we currently have antibody-drug conjugates that are conjugated to a cytotoxic chemotherapy. So are there oncogenic proteins that we can actually target that we couldn’t traditionally target with just a small molecule inhibitor? We look at ADCs. Unfortunately, these drugs are quite toxic.

Compounding Pharmacies 65

Compounding Pharmacies Immunization Hospitals Compounding 65

Pharmacy Times

JUNE 27, 2025

After learning of his diagnosis, our relationship shifted from small talk at school events to detailed discussions in an infusion center setting about chemotherapy, immunotherapy, clinical trials, alternative medicines, and anticipated adverse effects.

Compounding Pharmacies 50

Compounding Pharmacies Immunization Chemotherapy Hospitals 50

Pharmacy Times

JUNE 11, 2025

Additionally, patients may have received prior chemotherapy for advanced disease. Additionally, taletrectinib was granted priority review, breakthrough designation, and orphan drug designation for this indication. For both trials, the major efficacy outcomes were confirmed overall response rate (cORR) and duration of response (DOR).

FDA 73

FDA Compounding Pharmacies Immunization Hospitals 73

Pharmacy Times

JUNE 9, 2025

Newsletter Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights. Subscribe Now!

Compounding Pharmacies 56

Compounding Pharmacies FDA Hospitals Immunization 56

Pharmacy Times

JUNE 25, 2025

Benmelstobart (TQB2450; Chia Tai Tianqing Pharmaceutical Group Co, Ltd) in combination with chemotherapy followed by sequential combination with anlotinib (Catequentinib; Advenchen Laboratories) led to significant improvements in progression-free survival (PFS), with a manageable safety profile. months versus 7.79 months with tislelizumab.

Chemotherapy 50

Chemotherapy Compounding Pharmacies Immunization Compounding 50

Pharmacy Times

JUNE 18, 2025

News All News FDA Updates Press Releases Media All Videos Digital Detail Independent Corner Insights Interviews MEDcast Medical World News Microsites Peer Exchange Perfect Consult Podcasts Practice Pearls Sponsored Webcast Student Voices Webinars/Webcasts Conferences Conference Coverage Conference Listing Publications Pharmacy Times Pharmacy Practice (..)

Compounding Pharmacies 73

Compounding Pharmacies Dosage Immunization Compounding 73

Pharmacy Times

JULY 14, 2025

TRE-515 Combined With a Radiopharmaceutical As a precision cancer treatment designed for adults with PSMA-positive mCRPC, lutetium Lu 177 vipivotide tetraxetan is used after individuals have undergone other treatments like androgen receptor pathway inhibition and taxane-based chemotherapy.

FDA 73

FDA Compounding Pharmacies Compounding Immunization 73

Pharmacy Times

JUNE 18, 2025

Mok : Right now, we have a lot of chemotherapy being used, but there are many more novel treatments being studied, especially in earlier lines of treatment. Bispecifics are moving up in the lymphoma space, and these newer therapies may have some synergistic effects with chemotherapy. REFERENCES 1. Updated August 18, 2021.

Chemotherapy 65

Chemotherapy Compounding Pharmacies Immunization Hospitals 65

Pharmacy Times

JULY 3, 2025

So we are licensed by the medical board and also by the board of pharmacy. So we'll send the prescriptions that they need to our specialty pharmacy and then get those meds and bring them to the patient prior to them ever coming to transplant and go, “Okay, these are the meds you're going to take.

Specialty Pharmacies 65

Specialty Pharmacies Compounding Pharmacies Hospitals Immunization 65

Pharmacy Times

JUNE 19, 2025

1 Biomarker testing is relatively new in the treatment landscape for NSCLC but has proven incredibly important for personalizing patient care, transforming from a generic chemotherapy approach to a highly personalized, genomically driven treatment strategy. For advanced disease, chemotherapy was the standard.

Chemotherapy 73

Chemotherapy Compounding Pharmacies Hospitals Immunization 73

Pharmacy Times

JUNE 25, 2025

link] Newsletter Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights. Subscribe Now!

Compounding Pharmacies 73

Compounding Pharmacies Immunization Chemotherapy Compounding 73

Pharmacy Times

JUNE 6, 2025

News All News FDA Updates Press Releases Media All Videos Digital Detail Independent Corner Insights Interviews MEDcast Medical World News Microsites Peer Exchange Perfect Consult Podcasts Practice Pearls Sponsored Webcast Student Voices Webinars/Webcasts Conferences Conference Coverage Conference Listing Publications Pharmacy Times Pharmacy Practice (..)

Compounding Pharmacies 65

Compounding Pharmacies Immunization Chemotherapy Compounding 65

Pharmacy Times

JUNE 18, 2025

News All News FDA Updates Press Releases Media All Videos Digital Detail Independent Corner Insights Interviews MEDcast Medical World News Microsites Peer Exchange Perfect Consult Podcasts Practice Pearls Sponsored Webcast Student Voices Webinars/Webcasts Conferences Conference Coverage Conference Listing Publications Pharmacy Times Pharmacy Practice (..)

Compounding Pharmacies 73

Compounding Pharmacies Dosage Immunization Compounding 73

Pharmacy Times

JUNE 17, 2025

Martino, PharmD, BCOP, APh Kaitlyn Wells, PharmD Sam Martinez, PharmD, BCOP, BCPS Craig A. Stevens, PharmD, BCPS June 3rd 2025 S2. Martino, PharmD, BCOP, APh Kaitlyn Wells, PharmD Sam Martinez, PharmD, BCOP, BCPS Craig A. Stevens, PharmD, BCPS June 3rd 2025 S2.

Compounding Pharmacies 65

Compounding Pharmacies Hospitals Immunization Chemotherapy 65

Pharmacy Times

JUNE 23, 2025

Datopotamab deruxtecan-dlnk (Datroway, Daiichi Sankyo, Inc) received FDA approval for treatment of adults with locally advanced or metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) who have received prior EGFR-directed therapy and platinum-based chemotherapy.

FDA 86

FDA Compounding Pharmacies Chemotherapy Immunization 86

Pharmacy Times

JUNE 9, 2025

link] Newsletter Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights. Subscribe Now!

Compounding Pharmacies 73

Compounding Pharmacies Immunization Chemotherapy Compounding 73